Explore Watchlists Pricing

kainos loboratories,inc (4556) Income statement

Market cap

¥10.4B

P/E ratio

16x

Kainos manufactures diagnostic pharmaceuticals, laboratory reagents, and medical devices for hospitals and research facilities to improve healthcare quality.

Summary Financials Dividends History Ownership Workforce

Income statement Balance sheet Cash flow Other

	2012/03	2013/03	2014/03	2015/03	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03	2024/03	2025/03	2026/03
Revenue	4,864	5,471	5,803	5,476	5,346	4,703	4,387	4,671	4,609	4,258	4,615	4,923	5,056	5,306	5,480
Revenue growth (%)	-
Cost of revenue	-	-	-	3,418	3,225	2,532	2,364	2,392	2,230	1,947	2,207	2,410	2,505	2,631	2,887
Gross profit	-	-	-	2,058	2,121	2,172	2,022	2,278	2,379	2,311	2,407	2,513	2,552	2,674	2,592
Gross margin (%)	-	-	-
Operating margin (%)	-	-	-
Operating expenses	-	-	-	1,657	1,678	1,697	1,566	1,697	1,770	1,679	1,660	1,692	1,687	1,851	1,845
Operating income	-	-	-	401	442	475	456	581	609	632	748	821	865	824	747
Income before tax	207	252	314	393	441	468	477	597	616	654	778	854	929	828	789
Pretax margin (%)	4.3	4.6	5.4	7.2	8.2	10	10.9	12.8	13.4	15.4	16.9	17.3	18.4	15.6	14.4
Provision for income taxes	-	-	-	148	141	148	101	204	201	195	255	277	292	186	185
Effective tax rate (%)	-	-	-
Net income	113	154	193	230	296	310	278	386	399	417	512	568	638	641	449
Earnings per share	25.42	34.57	43.37	51.73	69.39	74.12	66.49	98.57	97.09	100.63	126.39	136.13	152.26	152.06	106.19
Dividend per share	-	-	-	-	-	-	-	-	15	15	25	25	32	35	-